SCHEMBL4052625

SCHEMBL4052625

CC(C)c1cccc(C([NH])=O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 1/20 0.50
▸ RXRB P28702 1/20 0.50
▸ RXRG P48443 1/20 0.50
▸ SMN1; SMN2 Q16637 4/20 0.48
▸ MAPT P10636 3/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ ALDH1A1 P00352 2/20 0.48
▸ CYP3A4 P08684 2/20 0.48
▸ HPGD P15428 2/20 0.48
▸ HDAC4 P56524 2/20 0.48
▸ HDAC8 Q9BY41 2/20 0.48
▸ MDM4 O15151 1/20 0.48
▸ CA1 P00915 1/20 0.48
▸ CA2 P00918 1/20 0.48
▸ TP53 P04637 1/20 0.48
▸ TYR P14679 1/20 0.48
▸ ALOX15 P16050 1/20 0.48
▸ ALOX12 P18054 1/20 0.48
▸ CA5A P35218 1/20 0.48
▸ HTT P42858 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11756980 0.83 MAPT (0.65) RXRARXRBRXRGSMN1; SMN2MAPT
SCHEMBL30444032 0.82 RXRA (0.66) RXRARXRBRXRGSMN1; SMN2MAPT
SCHEMBL2737366 0.82 RXRA (0.51) RXRARXRBRXRGSMN1; SMN2MAPT
SCHEMBL3887369 0.82 RXRA (0.51) RXRARXRBRXRGSMN1; SMN2MAPT
SCHEMBL105264 0.82 RXRA (0.66) RXRARXRBRXRGSMN1; SMN2MAPT
SCHEMBL23775748 0.80 RXRA (0.50) RXRARXRBRXRGSMN1; SMN2MAPT
SCHEMBL2623891 0.80 KDM4E (0.50) RXRARXRBRXRGSMN1; SMN2MAPT
Ethane SCHEMBL5407515 0.80 RXRA (0.50) RXRARXRBRXRGSMN1; SMN2MAPT
SCHEMBL84456 0.80 PARP1 (0.57) RXRARXRBRXRGSMN1; SMN2MAPT
Hydrogen Peroxide SCHEMBL9061056 0.80 RXRA (0.54) RXRARXRBRXRGSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1856083-A4 CHROMEN-4-ONE INHIBITORS OF ANTI-APOPTOTIC BCL-2 FAMILY MEMBERS AND THE USES THEREOF UNIV MICHIGAN (US) 2009-05-27 — — EP disclosed
EP-1856083-A2 CHROMEN-4-ONE INHIBITORS OF ANTI-APOPTOTIC BCL-2 FAMILY MEMBERS AND THE USES THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2007-11-21 — — EP disclosed
US-20060247305-A1 Chromen-4-one inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2006-11-02 — — US disclosed
WO-2006099193-A2 CHROMEN-4-ONE INHIBITORS OF ANTI-APOPTOTIC BCL-2 FAMILY MEMBERS AND THE USES THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2006-09-21 — — WO disclosed
EP-0765879-B1 13-Substituted milbemycin 5-oxime derivatives, their preparation and their use against insects and other pests SANKYO CO (JP) 2001-02-14 — — EP disclosed
US-5861429-A MITICIDES AND ANTHELMINTICS SANKYO COMPANY, LIMITED (JP) 1999-01-19 — — US disclosed
EP-0765879-A1 13-Substituted milbemycin 5-oxime derivatives, their preparation and their use against insects and other pests SANKYO COMPANY LIMITED (JP) 1997-04-02 — — EP disclosed
US-4792628-A ANTIOXIDANTS, ANTIINFLAMMATORY AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1988-12-20 — — US disclosed
US-4698091-A 2-phenylpyrimidines, 2-naphthylpyrimidines and 2-heterocyclylpyrimidines as safeners for protecting cultivated plant against phytotoxic damage caused by herbicides CIBA-GEIGY CORPORATION (US) 1987-10-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247305-A1 Chromen-4-one inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof BCL2, BAD, BAX RXRA 2299/4885RXRB 1856/4885RXRG 1443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback